Literature DB >> 20523352

IBD: selective nanoparticle adhesion can enhance colitis therapy.

Alf Lamprecht.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20523352     DOI： 10.1038/nrgastro.2010.66

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  12 in total

1.  An oral drug delivery system targeting immune-regulating cells ameliorates mucosal injury in trinitrobenzene sulfonic acid-induced colitis.

Authors:  H Nakase; K Okazaki; Y Tabata; S Uose; M Ohana; K Uchida; T Nishi; A Debreceni; T Itoh; C Kawanami; M Iwano; Y Ikada; T Chiba
Journal:  J Pharmacol Exp Ther       Date:  2001-06       Impact factor: 4.030

2.  High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy.

Authors:  R J Farrell; A Murphy; A Long; S Donnelly; A Cherikuri; D O'Toole; N Mahmud; P W Keeling; D G Weir; D Kelleher
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

3.  A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles.

Authors:  Alf Lamprecht; Hiromitsu Yamamoto; Hirofumi Takeuchi; Yoshiaki Kawashima
Journal:  J Control Release       Date:  2005-04-26       Impact factor: 9.776

4.  Epithelial heparin delivery via microspheres mitigates experimental colitis in mice.

Authors:  Yann Pellequer; Yvette Meissner; Nathalie Ubrich; Alf Lamprecht
Journal:  J Pharmacol Exp Ther       Date:  2007-02-22       Impact factor: 4.030

5.  Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats.

Authors:  Alf Lamprecht; Hiromitsu Yamamoto; Hirofumi Takeuchi; Yoshiaki Kawashima
Journal:  J Pharmacol Exp Ther       Date:  2005-06-24       Impact factor: 4.030

6.  Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.

Authors:  Hamed Laroui; Guillaume Dalmasso; Hang Thi Thu Nguyen; Yutao Yan; Shanthi V Sitaraman; Didier Merlin
Journal:  Gastroenterology       Date:  2009-11-10       Impact factor: 22.682

7.  Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa.

Authors:  Boaz Tirosh; Nadine Khatib; Yechezkel Barenholz; Aviram Nissan; Abraham Rubinstein
Journal:  Mol Pharm       Date:  2009 Jul-Aug       Impact factor: 4.939

8.  Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis.

Authors:  L Pastorelli; S Saibeni; L Spina; C Signorelli; G Celasco; R de Franchis; M Vecchi
Journal:  Aliment Pharmacol Ther       Date:  2008-09-01       Impact factor: 8.171

9.  The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis.

Authors:  Brice Moulari; David Pertuit; Yann Pellequer; Alf Lamprecht
Journal:  Biomaterials       Date:  2008-09-13       Impact factor: 12.479

Review 10.  Therapeutic nanoparticles for drug delivery in cancer.

Authors:  Kwangjae Cho; Xu Wang; Shuming Nie; Zhuo Georgia Chen; Dong M Shin
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531
View more
  24 in total

1.  Heparin-Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine.

Authors:  Sufeng Zhang; Won Joon Cho; Amy T Jin; Lie Yun Kok; Yunhua Shi; David E Heller; Young-Ah Lucy Lee; Yixuan Zhou; Xi Xie; Joshua R Korzenik; Jochen K Lennerz; Giovanni Traverso
Journal:  Adv Healthc Mater       Date:  2020-06-29       Impact factor: 9.933

Review 2.  Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.

Authors:  Madharasi V A Pichai; Lynnette R Ferguson
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

Review 3.  Engineered nanoparticulate drug delivery systems: the next frontier for oral administration?

Authors:  Roudayna Diab; Chiraz Jaafar-Maalej; Hatem Fessi; Philippe Maincent
Journal:  AAPS J       Date:  2012-07-06       Impact factor: 4.009

Review 4.  Nanomedicines in gastroenterology and hepatology.

Authors:  Alf Lamprecht
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-10       Impact factor: 46.802

5.  Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease.

Authors:  Sufeng Zhang; Robert Langer; Giovanni Traverso
Journal:  Nano Today       Date:  2017-10-09       Impact factor: 20.722

6.  Budesonide Loaded PLGA Nanoparticles for Targeting the Inflamed Intestinal Mucosa--Pharmaceutical Characterization and Fluorescence Imaging.

Authors:  Hussain Ali; Benno Weigmann; Eva-Maria Collnot; Saeed Ahmad Khan; Maike Windbergs; Claus-Michael Lehr
Journal:  Pharm Res       Date:  2015-12-30       Impact factor: 4.200

7.  Glycoprotein CD98 as a receptor for colitis-targeted delivery of nanoparticle.

Authors:  Bo Xiao; Yang Yang; Emilie Viennois; Yuchen Zhang; Saravanan Ayyadurai; Mark Baker; Hamed Laroui; Didier Merlin
Journal:  J Mater Chem B       Date:  2014-03-21       Impact factor: 6.331

8.  Vasoactive Intestinal Peptide Nanomedicine for the Management of Inflammatory Bowel Disease.

Authors:  Dulari Jayawardena; Arivarasu N Anbazhagan; Grace Guzman; Pradeep K Dudeja; Hayat Onyuksel
Journal:  Mol Pharm       Date:  2017-10-19       Impact factor: 4.939

9.  Dual Functional Eudragit® S100/L30D-55 and PLGA Colon-Targeted Nanoparticles of Iridoid Glycoside for Improved Treatment of Induced Ulcerative Colitis.

Authors:  Chenzhe Gao; Shen Yu; Xiaonan Zhang; Yanxin Dang; Dan-Dan Han; Xin Liu; Janchun Han; Mizhou Hui
Journal:  Int J Nanomedicine       Date:  2021-02-24

10.  Effects of oridonin nanosuspension on cell proliferation and apoptosis of human prostatic carcinoma PC-3 cell line.

Authors:  Zhen Zhang; Xiumei Zhang; Wei Xue; Yuna Yangyang; Derong Xu; Yunxue Zhao; Haiyan Lou
Journal:  Int J Nanomedicine       Date:  2010-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.